$TECH: Dr.
Filed with the SEC on · Summarized by InvestorsBot
$TECH: Dr. Matt McManus will transition from President, Diagnostics & Spatial Biology effective Mar 1, 2026; Board approved his termination on Feb 9, 2026. Steve Crouse (52), SVP Analytical Solutions, named DSS President effective Mar 1. 🧬📢 #Biotech #ExecChange
$TECH: Steve Crouse’s pay starts Mar 1: $505,000 base, cash incentive target 75% of salary. One‑time equity: ~$42.5k options, ~$42.5k RSUs, $85k PSUs (target). Annual equity targets: ~$300k options, $300k RSUs, $600k PSUs. 💼💸 #Compensation #Leadership
$TECH: Vesting: options 4 yrs, RSUs 3 yrs; PSUs contingent on FY2026–2028 performance. Severance if terminated w/o Cause/after Change‑in‑Control/or for Good Reason: 1 yr base, prorated bonus, 1 yr health (release required). No related‑party ties since 6/30/2023. ⚖️🧾 #SECfiling #Governance